Doxazosin nonclinical toxicology: Difference between revisions
Created page with "__NOTOC__ {{Doxazosin}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http:/..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==DRUG INTERACTIONS== | |||
Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that doxazosin has no effect on protein binding of [[digoxin]], [[warfarin]], [[phenytoin]], or [[indomethacin]]. There is no information on the effect of other highly plasma protein- bound drugs on doxazosin binding. Doxazosin has been administered without any evidence of an adverse drug interaction to patients receiving [[thiazide ]]diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral [[cimetidine ]](400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown. | |||
In clinical trials, doxazosin tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. Doxazosin tablets have been used with the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g., [[acetaminophen]], [[aspirin]], [[codeine ]]and [[codeine ]]combinations, [[ibuprofen]], [[indomethacin]]); 2) antibiotics (e.g., [[erythromycin]], [[trimethoprim ]]and [[sulfamethoxazole]], [[amoxicillin]]); 3) antihistamines (e.g., [[chlorpheniramine]]); 4) cardiovascular agents (e.g., [[atenolol]], [[hydrochlorothiazide]], [[propranolol]]); 5) [[corticosteroids]]; 6) gastrointestinal agents (e.g., [[antacids]]); 7) hypoglycemics and endocrine drugs; 8) sedatives and tranquilizers (e.g., [[diazepam]]); 9) cold and flu remedies. | |||
Concomitant administration of doxazosin with a [[PDE5 inhibitor|phosphodiesterase-5 ]](PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see[[Doxazosin dosage and administration|DOSAGE AND ADMINISTRATION]]).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 05:11, 7 March 2014
| Doxazosin |
|---|
| Doxazosin®, Cardura® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Doxazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
DRUG INTERACTIONS
Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that doxazosin has no effect on protein binding of digoxin, warfarin, phenytoin, or indomethacin. There is no information on the effect of other highly plasma protein- bound drugs on doxazosin binding. Doxazosin has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown.
In clinical trials, doxazosin tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. Doxazosin tablets have been used with the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin); 2) antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin); 3) antihistamines (e.g., chlorpheniramine); 4) cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol); 5) corticosteroids; 6) gastrointestinal agents (e.g., antacids); 7) hypoglycemics and endocrine drugs; 8) sedatives and tranquilizers (e.g., diazepam); 9) cold and flu remedies.
Concomitant administration of doxazosin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (seeDOSAGE AND ADMINISTRATION).[1]
References
- ↑ "DOXAZOSIN TABLET [APOTEX CORP.]". Retrieved 7 March 2014.